Cancer Genetics and Epigenetics 2017, Vol.5, No.7, 33-38
38
Le Mercier I., Lines J.L., and Noelle R.J., 2015, Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators, Front Immunol, 6: 418
PMid:26347741 PMCid:PMC4544156
Li J.H., Zhu Y., Yang J., and Qin L.X., 2016, The progress in tumor immune checkpoint-targeted immunotherapy, Fudan Univ J Med Sci, 43(1): 110-114
Mayer A.T., Natarajan A., Gordon S.R., Maute R.L., McCracken M.N., Ring A.M., Weissman I.L., and Gambhir S.S., 2017, Practical immuno-PET radiotracer
design considerations for human immune checkpoint imaging, J Nucl Med, 58(4): 538-546
PMid:27980047 PMCid:PMC5373501
Maute R.L., Gordon S.R., and Mayer A.T., McCrackena M.N., Natarajane A., Ring N.G., Kimurae R., Tsai J.M., Manglikg A., Kruseh A.C., Gambhir S.S.,
Weissman I.L., and Ring A.M., 2015, Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging, PNAS, 112(47):
E6506
PMid:26604307 PMCid:PMC4664306
Muyldermans S., 2013, Nanobodies: natural single-domain antibodies, Annu Rev Biochem, 82: 775-97
PMid:23495938
Parra E.R., Behrens C., Rodriguez-Canales J., Lin H., Mino B., Blando J., Zhang J., Gibbons D.L., Heymach J.V., Sepesi B., Swisher S.G., Weissferdt A.,
Kalhor N., Izzo J., Kadara H., Moran C., Lee J.J., and Wistuba I.I., 2016, Image analysis-based assessment of PD-L1 and tumor-associated immune cells
density supports distinct intratumoral microenvironment groups in non-small cell lung carcinoma patients, Clin Cancer Res., 22(24): 6278-6289
PMid:27252415 PMCid:PMC5558040
Parry R.V., Chemnitz J.M., Frauwirth K.A., Lanfranco A.R., Braunstein I., Kobayashi S.V., Linsley P.S., Thompson C.B., and Riley J.L., 2005, CTLA-4 and
PD-1 receptors inhibit T-cell activation by distinct mechanisms, Mol Cell Biol, 25(21): 9543-53
PMid:16227604 PMCid:PMC1265804
Topalian S.L., Drake C.G., and Pardoll D.M., 2015, Immune checkpoint blockade: a common denominator approach to cancer therapy, Cancer Cell, 27(4):
450-61
PMid:25858804 PMCid:PMC4400238
van Dongen G.A., and Vosjan M.J., 2010, Immuno-positron emission tomography: shedding light on clinical antibody therapy, Cancer Biother Radiopharm,
25(4): 375-85
PMid:20707716
Walker L.S., and Sansom D.M., 2015, Confusing signals: recent progress in CTLA-4 biology, Trends in Immunology, 36(2): 63-70
PMid:25582039 PMCid:PMC4323153
Wang X., Teng F., Kong L., and Yu J., 2016, PD-L1 expression in human cancers and its association with clinical outcomes, Onco Targets Ther, 9: 5023-39
PMid:27574444 PMCid:PMC4990391
Wang L.Z., and Yang M, 2016, Development of 89Zr labelled radiopharmaceuticals, Journal of Isotopes, 29(2): 121-128
Wittrup K.D., Thurber G.M., Schmidt M.M., and Rhoden J.J., 2012, Practical theoretic guidance for the design of tumor-targeting agents, Methods Enzymol,
503: 255-68
PMid:22230572 PMCid:PMC3978464
Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., Burke M.M., Caldwell A.,
Kronenberg S.A., Agunwamba B.U., Zhang X., Lowy I., Inzunza H.D., Feely W., Horak C.E., Hong Q., Korman A.J., Wigginton J.M., Gupta A., and
Sznol M., 2013, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, 369(2): 122-33
PMid:23724867 PMCid:PMC5698004
Wright B.D. and Lapi S.E., 2013, Designing the magic bullet? The advancement of immuno-PET into clinical use, J Nucl Med, 54(8): 1171-4
PMid:23908265
